herpes%20simplex%20virus%20infection
HERPES SIMPLEX VIRUS INFECTION
Primary herpes simplex virus (HSV) infection is first infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2.
First episode-non primary infection is infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively.
Recurrent HSV infection results from reactivation of latent virus. It is usually brought about by triggering factors eg UV light, immunosuppression.
Orolabial HSV disease is mostly caused by HSV-1 that occurs most commonly in children <5 years of age. It is transmitted through close contact with individuals who have active viral shedding.
Genital HSV disease is caused by HSV-2 that is the usual cause of herpes genitalis. It typically occurs in adults and transmitted through sexual contact.

Prevention

  • Educate patient on how to prevent transmission by:
    • Abstaining from sexual contact during lesion recurrences or prodromes
    • Limiting the number of sexual partners
    • Informing sexual partner or former sexual partner(s) from preceding 60 days prior to diagnosis to seek evaluation & treatment
    • Understanding that asymptomatic viral shedding may cause transmission
      • Asymptomatic viral shedding is more likely to occur w/ HSV-2 infection, in the 1st year following an infection, or if recurrences are symptomatic; however, shedding decreases w/ time
    • Using a condom to protect against transmission (not foolproof)
    • Taking daily suppressive antiviral therapy which decreases recurrent genital lesions, asymptomatic viral shedding & transmission

Management Strategies for Recurrent Genital Herpes

Supportive Treatment Alone
  • Recurrent infections are generally self-limiting, less severe w/ a shorter duration of symptoms & supportive treatment alone may be effective to control symptoms
Episodic Antiviral Treatment
  • Patient-initiated therapy that needs to be pre-prescribed
    • Start antiviral therapy as soon as possible within 1 day of lesion onset or during the prodrome that heralds some outbreak
  • Best for HSV-infected patients who have mild symptoms & infrequent recurrences
  • Reduces duration of symptoms by 1-2 days
Suppressive Antiviral Therapy
  • Recommended in patients w/ frequent recurrent genital herpes (≥6 episodes/year), severe or painful prodromes, pregnant patients w/ herpetic lesions in the last trimester, patients w/ psychological problems due to the infection, & in immunocompromised patients
  • Used to decrease frequency of recurrences, chance of transmission & provide relief of symptoms
  • Antiviral suppress symptomatic & asymptomatic viral shedding
    • Reduces clinical outbreaks & viral shedding by 80% & 95% respectively
  • Full suppressive effect is usually obtained when in treatment for 5 days
  • Outbreaks during therapy should investigate for poor compliance, need for dose adjustments, resistance or incorrect diagnosis
  • Annual evaluation & cessation of therapy after 1 year is required to assess frequency of recurrences
    • Period of assessment should include 2 recurrences to view both severity & frequency
    • It is safe & advisable to restart suppressive treatment in patients who continue to have significant infection
  • Suppressive treatment may incur higher costs & inconvenience

Counselling

Patient & Parent

  • Reduce patient’s anxiety & help patients to cope w/ the infection by educating them on the natural history of the disease, recurrent episodes, antiviral treatments, sexual relationships & perinatal transmission
  • Discuss treatment options:
    • Episodic treatment vs suppressive treatment
    • If patient has ≥6 episodes/year, consider suppressive treatment
    • Suppressive treatment may incur higher costs & inconvenience
      • Increase fluid intake to dilute urine

Follow Up

  • Interrupt treatment after 6 months-1 year to assess frequency of recurrence
  • Restart treatment if high rate of recurrences
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, 18 hours ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.